SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 741.91-1.6%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (59)3/25/1997 12:06:00 AM
From: Miljenko Zuanic   of 3559
 
James,

P&G deal is for early stage-mostly core research in muscular atrophy. If necessary they can put together group responsible for clinical study. Also REGN will have to create separate department. The deal is more important for REGN than for P&G.
AMGN buyout do make sense, but not at this stage. Without prove that BDNF, NT-3, CNTF, and other neuroprotective factors (REGN has excellent expertise in receptors for this grow factors, but incredible bad luck in clinical) AMGN will stay aside or maybe pull-off from partnership. Because I still have REGN, I hope REGN will have positive results on ongoing trials. Also, REGN have good research projects, which will be hard to valued. This value is usually higher than bidder is willing to pay.
How will things develop, difficult to predict.

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News